Aldeyra Therapeutics Inc

NASDAQ:ALDX  
6.90
-0.43 (-5.87%)
Products, Regulatory, Other Pre-Announcement

Aldeyra Therapeutics Completes Enrollment In Phase 3 Trial In Patients With Dry Eye Disease

Published: 11/09/2021 13:14 GMT
Aldeyra Therapeutics Inc (ALDX) - Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 Tranquility Trial in Patients With Dry Eye Disease and Reiterates New Drug Application (nda) Submission Guidance.
Aldeyra Therapeutics Inc - Top-line Results From Tranquility Expected This Quarter.
Aldeyra Therapeutics Inc - Anticipated NDA Submission Expected in Early 2022.